Mirum Pharmaceuticals, Inc.
AZURE 2 & 3
Hepatitis Delta Virus
Countdown
724days
Phase 3 readout · ~ Jun 30, 2028 estimated
What's at stake
Phase 3 trial results for AZURE 2 & 3 in Hepatitis Delta Virus are due ~ Jun 30, 2028. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“AZURE 2 & 3, Phase 3 topline data expected H1 2028 (EU registrational program)”